Rezolute is trading 5.6% down at $3.73, with no clear company-specific catalyst identified for September 18, 2026.
- FDA review of additional ersodetug data continues after the Phase 3 sunRIZE study missed its primary endpoint, with no timeline for feedback.
- Biotech is stronger overall, while major U.S. indexes are only modestly lower, so the decline is not clearly explained by sector or market direction.